Page last updated: 2024-12-04

7-hydroxy-2-n,n-dipropylaminotetralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1219
CHEMBL ID285755
CHEBI ID111176
SCHEMBL ID623950
MeSH IDM0098564

Synonyms (58)

Synonym
BRD-A18795974-001-01-2
(+)7-oh-dpat
gtpl950
(+)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide
7-ohdpat
7-(dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol
n,n-di-n-propyl-7-hydroxy-2-aminotetralin
2-naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-
7-hydroxy-n,n-di-n-propyl-2-aminotetralin
dp-7-at
7-hydroxy-2-n,n-dipropylaminotetralin
BIOMOL-NT_000011
PDSP2_001627
LOPAC0_000616
7-oh-dpat
NCGC00024742-03
PDSP1_001643
BPBIO1_001143
NCGC00024742-02
74938-11-7
7-hydroxy-2-(di-n-propylamino)tetralin
CHEBI:111176
NCGC00015494-06
CHEMBL285755 ,
L000014
(+/-)-7-oh-dpat
bdbm50020222
7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-2-ol (dp-7-adtn)
(r,s) 7-dipropylamino-5,6,7,8-tetrahydro-naphthalen-2-ol
7-oh-dpat,(+)
(+/-)-7-hydroxy-2-(n,n-di-n-propylamino)tetralin
7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol
(+/-)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol
7-oh-dpat,(-)
7-hydroxy-2-(dipropylamino)tetralin
CCG-204705
unii-rr7d75ydf4
rr7d75ydf4 ,
82730-73-2
NCGC00015494-05
NCGC00015494-04
AKOS015913437
gtpl3296
[3h]7-oh-dpat
[3h]-7-oh-dpat
SCHEMBL623950
2-(di-n-propylamino)-7-hydroxytetralin
7-hydroxy-n,n-dipropyl-2-aminotetralin
7-hydroxy-2-(di-n-propylamino)tetralin, (+/-)-
n,n-dipropyl-7-hydroxy-2-aminotetralin
DTXSID00874864
Q6593984
BRD-A18795974-004-02-4
SDCCGSBI-0050598.P002
NCGC00015494-11
7-hydroxy-dpat middot hbr
(7s)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol
2-naphthalenol,7-(dipropylamino)-5,6,7,8-tetrahydro-,(s)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The drugs 7-OH-DPAT, quinpirole and RU24213 were studied alone and in combination with cocaine for their effects on locomotor activity in non-habituated mice."( Dopamine 'D2-like' receptor agonists in combination with cocaine: absence of interactive effects on locomotor activity.
Reggers, J; Terry, P; Tirelli, E, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
" Compounds 6 and 8 were found to have high oral bioavailability in the rat (63% and 54%, respectively)."( 6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
Andersson, B; Carlsson, A; Ekman, A; Elebring, T; Lagerkvist, S; Nilsson, J; Stjernlöf, P; Svensson, K; Wikström, H, 1994
)
0.29
" The absolute oral bioavailability of compound 8 (8-triflate) was 4-5 times greater than the corresponding hydroxylated compound."( Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
Boije, M; Carlsson, A; Duncan, JN; Ekman, A; King, LJ; Martin, IJ; Romero, AG; Sonesson, C; Svensson, K; Wikström, H, 1993
)
0.29
" Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metabolism and increases bioavailability in the brain."( Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
Chen, JC; Hsieh, YT; Kuo, YH; Lao, CL, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" When responding was stable, dose-response curves were determined for cocaine (0."( Self-administration of the dopamine D3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure.
Mach, RH; Nader, MA, 1996
)
0.29
"0 microgram) administered into the 4th cerebral ventricle dose dependently induced emesis within 1 min of dosing in ferrets."( Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret.
Hosoki, K; Yoshida, N; Yoshikawa, T, 1996
)
0.29
" This dose-response pattern across ontogeny closely resembles that induced by quinpirole, an agonist at the dopamine D2 receptor subfamily."( The locomotor effects of a putative dopamine D3 receptor agonist in developing rats.
Babcock, D; Frantz, K; Van Hartesveldt, C, 1996
)
0.29
" The effects of the D3 agonists were dependent upon dosage and time after administration."( Dopamine D3 agonists disrupt social behavior in rats.
Furuya, Y; Hashimoto, T; Kagaya, T; Kuroki, J; Nishizawa, Y; Yonaga, M, 1996
)
0.29
"1 mg/kg 7-OH-DPAT on d-amphetamine (0-10 mg/kg) dose-response curves for the same behaviors were examined."( Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference.
Baker, DA; Fuchs, RA; Khroyan, TV; Manders, N; Neisewander, JL, 1998
)
0.3
" Thus, the inhibitory dose-response effects of a D2-preferring [sulpride], a D3-preferring [U 99194A] and combination of varying doses of these antagonists [sulpride + U 99194A] were evaluated on the ability of the cited agonists to produce vomiting."( The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew).
Ahmad, B; Darmani, NA; Zhao, W, 1999
)
0.3
" An examination of the concentration-response relationship revealed that (+/-)-7-OH-DPAT and PD 128,907 both produced bell-shaped dose-response curves for c-fos induction."( Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons.
Audinot, V; Millan, MJ; Morris, BJ; Newman-Tancredi, A; Simpson, CS, 2000
)
0.31
"0 mg/kg) produced a rightward shift in the (+)-7-OH-DPAT dose-response curve."( Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A.
Baker, LE; Christian, AJ; Goodwin, AK, 2001
)
0.31
"0 mg/kg was more effective at shifting to the right the pramipexole dose-response curve in pramipexole-trained rats, while 32 mg/kg of the selective D3 antagonist PG01037 had little effect."( The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats.
Greedy, B; Grundt, P; Husbands, SM; Koffarnus, MN; Newman, AH; Woods, JH, 2009
)
0.35
"5mg/kg) produced a rightward shift in the dose-response curve for cocaine generalization."( Levo-tetrahydropalmatine attenuates cocaine self-administration under a progressive-ratio schedule and cocaine discrimination in rats.
Baker, DA; Becker, A; Li, SJ; Mantsch, JR; Peters, C; Valentine, A; Vranjkovic, O; Wisniewski, S; Yang, Z, 2010
)
0.36
" Microinjection of the preferential D(3) agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) into lobe 9 of the cerebellum significantly reduced spontaneous locomotor activity with a U-shaped dose-response curve."( Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats.
Andatsu, S; Kizu, T; Miyoshi, S; Ohno, Y; Sato, M; Shimizu, S; Sugiuchi, T; Tatara, A, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tetralinsCompounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.25890.003245.467312,589.2998AID2517
dopamine D1 receptorHomo sapiens (human)Potency0.14580.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency15.06770.100020.879379.4328AID488772; AID588453; AID588456
arylsulfatase AHomo sapiens (human)Potency0.03381.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.58930.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency10.00000.02245.944922.3872AID488983
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)Ki0.12630.00000.651810.0000AID1297533; AID1297536; AID461559; AID64158; AID64196
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.00400.00010.25675.8000AID384695; AID413926; AID425416; AID513739; AID65624; AID65625; AID65628
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki2.81000.00010.739610.0000AID4368
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.00290.00030.37088.1600AID65628
D(3) dopamine receptorHomo sapiens (human)Ki0.24030.00000.602010.0000AID1297534; AID1297537; AID388686; AID388687; AID388689; AID461560; AID65788
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.22180.00000.437510.0000AID384696; AID413925; AID425415; AID513738; AID65896; AID65911
Histamine H3 receptorRattus norvegicus (Norway rat)Ki0.27000.00010.29638.5110AID388689
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.02320.00030.26715.0700AID204618
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)0.03980.00000.18743.9000AID384698
D(3) dopamine receptorRattus norvegicus (Norway rat)Kd0.00070.00010.00050.0007AID65601
D(3) dopamine receptorHomo sapiens (human)EC50 (µMol)0.00050.00010.02470.6690AID384700
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.51.50000.00010.40364.8000AID88009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (109)

Processvia Protein(s)Taxonomy
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay IDTitleYearJournalArticle
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1345898Rat D3 receptor (Dopamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Sep-01, Volume: 89, Issue:17
Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.
AID1345833Human D3 receptor (Dopamine receptors)1995Journal of neuroimmunology, May, Volume: 58, Issue:2
Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT.
AID3602Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID384698Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID197169Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID3678350% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID384695Displacement of [3H]spiperone from rat dopamine D3 receptor expressed in HEK293 cells2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID61137Effective dose for half-maximal decrease in the accumulation of DOPA in reserpinized rat brain limbic area by sc administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID1297533Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
AID61005Effective dose for half-maximal decrease in the accumulation of DOPA in reserpinized rat brain hemispheral area by sc administration; Inactive1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID461560Displacement of [3H]spiperone from cloned dopamine D3 receptor expressed in HEK cells2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID177896Inhibition of dopamine accumulation in limbic part of rat brain after subcutaneous administration1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID180741The concentration yielding a half maximal decrease of the DOPA was determined in rat brain striatum. pED50 values in parenthesis1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID425415Displacement of [3H]spiperone from rat dopamine D2L receptor expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11
Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.
AID388689Displacement of [3H]spiperone from human D3 F6.51W mutant receptor expressed in human HEK293 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
AID461561Selectivity ratio of Ki for dopamine D2L receptor to Ki for dopamine D3 receptor2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID3608Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID388686Displacement of [3H]spiperone from human wild type D3 receptor expressed in human HEK293 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
AID384702Selectivity for human dopamine D3 receptor over human dopamine D2L receptor by [35S]GTPgammaS binding assay2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID181024Percent reduction of hemispheres in cortex was measured in the brain of reserpinized rats; I is Inactive, no significant effect at doses approximately 40 times the ED50 for Dopa accumulation1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID173496In Vivo effect on concentration of DOPAC in rat striatum at 1 umol/kg1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID425417Selectivity ratio of Ki for rat dopamine D2L receptor to Ki rat dopamine D3 receptor2009Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11
Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.
AID388687Displacement of [3H]spiperone from human D3 D3.32E mutant receptor expressed in human HEK293 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
AID36715Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID65081Binding affinity against dopamine receptor D2 in rat brain tissue using [3H]spiperone1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID3596Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID65628Tested for inhibition of the binding of [125I]NCQ298 to dopamine receptor D31993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID4368Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID388690Selectivity ratio of Ki for human wild type D3 receptor over Ki for human D3 F6.51W mutant receptor2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
AID1297538Selectivity index, ratio Ki for human D3 receptor to Ki for human D2 receptor using [3H]7-OH-DPAT displacement assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
AID226638Hill coefficient value.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID513739Displacement of [3H]spiperone from rat D3 receptor expressed in HEK293 cells2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID384700Agonist activity at human dopamine D3 receptor expressed in mouse ATt-20 cells assessed as stimulation of [35S]GTPgammaS binding2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID384699Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID192727post-synaptic agonistic effects by increase in locomotor activity at the dose of 1.0 umol/kg, sc in reserpinized rat1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID177121ED50 value was measured as dose required to produce a half-maximal reduction of Dopa accumulation in limbic area of reserpinized rat brain.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID1150433Dopaminergic activity in dog assessed as induction of emesis administered intramuscularly measured up to 20 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene.
AID65625Tested for binding affinity against dopamine receptor D3 expressed in Sf9 cells.1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID388688Selectivity ratio of Ki for human wild type D3 receptor over Ki for human D3 D3.32E mutant receptor2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
AID177284ED50 value was measured as dose required to produce a half-maximal reduction of Serotonin (5-HTP) accumulation in striatum of reserpinized rat brain; I is Inactive, no significant effect at doses approximately 40 times the ED50 for Dopa accumulation1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID180718The concentration yielding a half maximal decrease of the 5-HTP was determined in rat brain hemispheres; inactive at 11 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID4347Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
AID177870Inhibition of 5-Hydroxy tryptamine accumulation in hemispheres of rat brain after subcutaneous administration; I= Inactive1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID177127ED50 value was measured as dose required to produce a half-maximal reduction of Dopa accumulation in the striatum of reserpinized rat brain.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID461559Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID177278ED50 value was measured as dose required to produce a half-maximal reduction of Serotonin (5-HTP) accumulation in limbic area of reserpinized rat brain; I is Inactive, no significant effect at doses approximately 40 times the ED50 for Dopa accumulation1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Monophenolic octahydrobenzo[f]quinolines: central dopamine- and serotonin-receptor stimulating activity.
AID180727The concentration yielding a half maximal decrease of the 5-HTP was determined in rat limbic system; inactive at 11 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID204618Tested for the inhibitory activity against sigma receptor rat cerebellar1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
AID413926Displacement of [3H]Spiperone from rat dopamine D3 receptor expressed in HEK293 cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.
AID4216Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID224035Motor activity was measured by motility testing on injecting the compound subcutaneously into rats at the dose of 12.5 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID180722The concentration yielding a half maximal decrease of the 5-HTP was determined in rat brain striatum; inactive at 11 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID88009Displacement of [3H](-)-trans-H2-PAT from histamine H2 PAT binding site by competition binding assay.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID413925Displacement of [3H]Spiperone from rat dopamine D2L receptor expressed in HEK293 cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.
AID64196Tested for the inhibitory activity against D2H (high-affinity states) receptor in infected HEK 293 cells.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
AID177872Inhibition of 5-Hydroxy tryptamine accumulation in limbic part of rat brain after subcutaneous administration; I= Inactive1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID190413DA agonist induced behavior was charecterised by increased locomotion, sniffing and licking.+ indicates low intensity of behavioral effect1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID425416Displacement of [3H]spiperone from rat dopamine D3 receptor expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11
Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.
AID1297535Selectivity index, ratio Ki for human D3 receptor to Ki for human D2 receptor using [3H]N-methylspiperone displacement assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
AID384697Selectivity for rat dopamine D3 receptor over rat dopamine D2L receptor2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID177898Inhibition of dopamine accumulation in striatum part of rat brain after subcutaneous administration1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID513738Displacement of [3H]spiperone from rat D2 receptor expressed in HEK293 cells2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID61142Effective dose for half-maximal decrease in the accumulation of DOPA in reserpinized rat brain striatal area by sc administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
AID384696Displacement of [3H]spiperone from rat dopamine D2L receptor expressed in HEK293 cells2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID26626Ionization constant in presence of nitrogen1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID64158Inhibitory activity against [125I]- NCQ298 binding to dopamine receptor D2 in Sf 9 cells1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID384701Agonist activity at human dopamine D3 receptor expressed in mouse ATt-20 cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
AID173499In Vivo effect on concentration of HVA in rat striatum at 1 umol/kg1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID65788Tested for the inhibitory activity against Dopamine D3 receptor in infected Sf9 cells1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
AID4036Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID168912Potency to displace the specific in vitro binding of [3H]DP-5,6-ADTN to rat striatal membrane1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID65896Tested for inhibition of the binding of [125I]NCQ298 to D2 receptor1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID1297534Displacement of [3H]N-methylspiperone from human D3 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
AID65911Displacement of the radioligand [3H]spiperone from D2 receptor1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID177874Inhibition of 5-Hydroxy tryptamine accumulation in striatum part of rat brain after subcutaneous administration; I= Inactive1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
AID229808Ratio of Ki of D2 receptor to that of D3 receptor1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis of (R,S)-2'-trans-7-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin (trans-7-OH-PIPAT): a new D3 dopamine receptor ligand.
AID65601Tested for binding affinity against dopamine receptor D31993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Synthesis and optical resolution of (R)- and (S)-trans-7-Hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand.
AID54451Potency to displace the specific in vitro binding of [3H]N-0437 to calf striatal membrane1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID19222Partition coefficient in octanol-buffer at a pH 7.41988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID1297536Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
AID1150434Dopaminergic activity in sc dosed Sprague-Dawley rat assessed as induction of stereotyped behavior administered for 30 to 50 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene.
AID19560Hill coefficient of the compound1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID180751The concentration yielding a half maximal decrease of the DOPA was determined in rat limbic system. pED50 values in parenthesis1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID180734The concentration yielding a half maximal decrease of the DOPA was determined in rat brain hemispheres; inactive at 11 umol/kg1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
AID26837Ionization constant in presence of hydroxyl1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b ]-1,4-oxazin-7- and -9-ols: the significance of nitrogen pKa values for central dopamine receptor activation.
AID1297537Displacement of [3H]7-OH-DPAT from human D3 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
AID65624Inhibitory activity against [125I]- NCQ298 binding to dopamine receptor D3 in Sf 9 cells1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID413927Selectivity ratio of Ki for rat dopamine D2L receptor to Ki for rat dopamine D3 receptor expressed in HEK293 cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345833Human D3 receptor (Dopamine receptors)1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
AID1345833Human D3 receptor (Dopamine receptors)1995Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Jul, Volume: 12, Issue:4
Lack of discrimination by agonists for D2 and D3 dopamine receptors.
AID1345783Rat D2 receptor (Dopamine receptors)1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
AID1345833Human D3 receptor (Dopamine receptors)1995Neuroreport, Jan-26, Volume: 6, Issue:2
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
AID1345788Human D2 receptor (Dopamine receptors)1995Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Jul, Volume: 12, Issue:4
Lack of discrimination by agonists for D2 and D3 dopamine receptors.
AID1345788Human D2 receptor (Dopamine receptors)1994European journal of pharmacology, Jan-01, Volume: 266, Issue:1
Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
AID1345788Human D2 receptor (Dopamine receptors)1994The Journal of pharmacology and experimental therapeutics, Jan, Volume: 268, Issue:1
Expression and pharmacological characterization of the human D3 dopamine receptor.
AID1345833Human D3 receptor (Dopamine receptors)1994European journal of pharmacology, Jan-01, Volume: 266, Issue:1
Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
AID1345833Human D3 receptor (Dopamine receptors)1994The Journal of pharmacology and experimental therapeutics, Jan, Volume: 268, Issue:1
Expression and pharmacological characterization of the human D3 dopamine receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017Wombat Data for BeliefDocking1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
6,7,8,9-Tetrahydro-N,N-di-n-propyl-3H-benzindol-8-amines. Derivatives as potent and orally active serotonin 5-HT1A receptor agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (380)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (2.37)18.7374
1990's202 (53.16)18.2507
2000's131 (34.47)29.6817
2010's33 (8.68)24.3611
2020's5 (1.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.12 (24.57)
Research Supply Index5.99 (2.92)
Research Growth Index6.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other397 (99.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]